Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levornidazole Disodium Phosphate vs Levornidazole for Pelvic Anaerobic Infection
CTR20222190Phase 3Completed
- Sponsor
- Huachuang Synthetic Pharmaceutical
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levornidazole in Pelviabdominal infection, endometritis, Salpingitis, adnexitis, Tubo-ovarian abscess (TOA), sponsored by Huachuang Synthetic Pharmaceutical. Started Aug 2022; status: completed.
02
Drugs
levornidazole
03
Conditions
Pelviabdominal infectionendometritisSalpingitisadnexitisTubo-ovarian abscess (TOA)
Beyond the preview
Go deeper on CTR20222190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222190.